70. Spinal stenosis
91 clinical trials,   195 drugs   (DrugBank: 54 drugs),   60 drug target genes,   85 drug target pathways
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03647501 (ClinicalTrials.gov) | August 22, 2018 | 21/8/2018 | Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages | Lumbar Fusion With 3D-Printed Porous Titanium Interbody Cages - A Single-Blinded Randomized Controlled Trial Evaluating Nexxt Matrixx(TM) Versus PEEK Cages | Lumbar Degenerative Disc Disease;Lumbar Spinal Stenosis;Lumbar Spondylolisthesis;Lumbar Spinal Deformity;Lumbar Spondylosis | Device: Interbody cage (titanium);Device: Interbody cage (PEEK) | Ohio State University | Nexxt Spine, LLC | Recruiting | 18 Years | N/A | All | 70 | N/A | United States |
2 | NCT03532945 (ClinicalTrials.gov) | October 28, 2010 | 2/5/2018 | A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion | A Long-term Follow-up Study to Evaluate the Efficacy and Safety for the Patients With Bioactive Glass-ceramic Intervertebral Spacer (Novomax) in Posterior Lumbar Interbody Fusion: Comparison With a Titanium Cage | Degenerative Lumbar Spinal Stenosis | Device: Bioactive Glass-Ceramic Spacer;Device: Titanium cage | BioAlpha Inc. | NULL | Completed | 30 Years | 80 Years | All | 62 | N/A | NULL |